Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 191

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 191
---
 (“60P LLC”), entered into the Agreement and Plan of Merger with 60 Degrees Pharmaceuticals, Inc., pursuant to which 60P LLC merged into 60 Degrees Pharmaceuticals, Inc. The value of each outstanding member’s membership interest in 60P LLC was correspondingly converted into common stock of 60 Degrees Pharmaceuticals, Inc., par value $0.0001 per share, with a cost-basis equal to $60.00 per share. We also operate one subsidiary. A summary of our majority-owned subsidiary is below. We own 97% equity in 60P Australia Pty Ltd, a Sydney-Australia based subsidiary (“60P Australia”). 60P Australia holds sub-licensing rights for several ex-U.S. territories for our product. 60P Australia previously solely owned a Singaporean subsidiary company, 60P Singapore Pte. Ltd., which dissolved at our election in the second quarter of 2022. MANAGEMENT The following table sets forth the name, age and position of each of our executive officers, directors and director nominees as of February 14, 2025.

| Name           
 Geoffrey Dow   |     | Age 
  51 |     | Position                           
 Chief Executive Officer, President 
 and Director                       |     | Director      
 Since         
 June 1, 2022  |
|:---------------|:----|----:|:----|:-----------------------------------|:----|:--------------|
| Tyrone Miller  |     |  50 |     | Chief Financial Officer            |     |               |
| Kristen Landon |     |  58 |     | Chief Commercial Officer           |     |               |
| Charles Allen  |     |  49 |     | Director                           |     | July 11, 2023 |
| Cheryl Xu      |     |  57 |     | Director                           |     | July 11, 2023 |
| Stephen Toovey |     |  71 |     | Director                           |     | July 11, 2023 |
| Paul Field     |     |  62 |     | Director                           |     | July 11, 2023 |

Executive Officers and Directors Geoffrey Dowis our Chief Executive Officer, President, and is also one of our directors. Dr. Dow has over 20 years of product development experience in tropical diseases and has an extensive publication and patent history. His decades of hands-on experience include 13 years in key leadership and advisory roles in the antimalarial drug development program at the Walter